Hydrocortisone sodium succinate, sold under the brand name Solu-Cortef among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.[3]
Clinical data | |
---|---|
Trade names | Solu-Cortef |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous, intramuscular |
Drug class | Corticosteroid; Glucocorticoid |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.296 |
Chemical and physical data | |
Formula | C25H34NaO8 |
Molar mass | 485.529 g·mol−1 |
3D model (JSmol) | |
| |
|
Hydrocortisone sodium succinate was approved for medical use in the United States in 1955.[2]
References
edit- ^ "CIPLA HYDROCORTISONE, CORTI-H, CORTICIP, HYDROCIP (Cipla Australia Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
- ^ a b "Solu-Cortef- hydrocortisone sodium succinate injection, powder, for solution". DailyMed. 19 August 2021. Retrieved 23 December 2023.
- ^ Brownell CL, Priff N (2009). "Hydrocortisone". Nursing2009 Student Drug Handbook (10th ed.). Philadelphia: Wolters Kluwer. p. 642. ISBN 978-0-7817-8883-0.